scholarly article | Q13442814 |
P356 | DOI | 10.2217/IMT-2017-0121 |
P698 | PubMed publication ID | 29145737 |
P2093 | author name string | Martin Reck | |
P2860 | cites work | PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project | Q39135152 |
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Q40163779 | ||
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial | Q40346982 | ||
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) | Q42073978 | ||
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer | Q42407789 | ||
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. | Q48020812 | ||
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer | Q26471909 | ||
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? | Q26741101 | ||
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy | Q26745516 | ||
Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab | Q27712488 | ||
First-line crizotinib versus chemotherapy in ALK-positive lung cancer | Q27853101 | ||
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial | Q27853299 | ||
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial | Q27853360 | ||
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents | Q28087754 | ||
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer | Q29620301 | ||
Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. | Q30275719 | ||
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? | Q33296440 | ||
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial | Q37193792 | ||
Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy | Q37462524 | ||
The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. | Q38355766 | ||
The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysis | Q38538741 | ||
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. | Q38645064 | ||
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States. | Q38722972 | ||
Non-Small Cell Lung Cancer, PD-L1, and the Pathologist | Q38755369 | ||
Evaluation of dosing strategy for pembrolizumab for oncology indications | Q38779793 | ||
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Q38975751 | ||
P433 | issue | 2 | |
P921 | main subject | pembrolizumab | Q13896859 |
P304 | page(s) | 93-105 | |
P577 | publication date | 2017-11-17 | |
P1433 | published in | Immunotherapy | Q18713038 |
P1476 | title | Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer | |
P478 | volume | 10 |
Q55318335 | Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients? |
Q60922811 | Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle |
Q93231440 | Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation |
Q57185180 | Critical appraisal of PD-L1 reflex diagnostic testing: current standards and future opportunities |
Q93200655 | First-Line Systemic Treatments for Stage IV Non-Small Cell Lung Cancer in California: Patterns of Care and Outcomes in a Real-World Setting |
Q92469117 | Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study |
Q61445430 | Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15 |
Q64236602 | KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer |
Q64091350 | PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions |
Q92400317 | Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study |
Q55398181 | Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. |
Q89666795 | Pleurodesis and Immunotherapy in NSCLC; Medical Thoracoscopy or VATS? |
Q57299127 | Predictive pathology of lung cancer immunotherapy response |
Q52663125 | Progress in the Management of Malignant Pleural Mesothelioma in 2017. |
Q91831510 | Radioimmunoimaging of 125I-labeled anti-CD93 monoclonal antibodies in a xenograft model of non-small cell lung cancer |
Q58089143 | Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade |
Q103836615 | SKIL facilitates tumorigenesis and immune escape of NSCLC via upregulating TAZ/autophagy axis |
Q90446250 | The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma |
Q64882422 | Video-assisted thoracic surgery double sleeve resections: the next step. |
Q91654615 | What is the potential use of platelet-rich-plasma (PRP) in cancer treatment? A mini review |
Q92728812 | [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer] |